Pomegranate Extract Affects Fungal Biofilm Production: Consumption of Phenolic Compounds and Alteration of Fungal Autoinducers Release

Int J Environ Res Public Health. 2022 Oct 29;19(21):14146. doi: 10.3390/ijerph192114146.

Abstract

Candida albicans expresses numerous virulence factors that contribute to pathogenesis, including its dimorphic transition and even biofilm formation, through the release of specific quorum sensing molecules, such as the autoinducers (AI) tyrosol and farnesol. In particular, once organized as biofilm, Candida cells can elude conventional antifungal therapies and the host's immune defenses as well. Accordingly, biofilm-associated infections become a major clinical challenge underlining the need of innovative antimicrobial approaches. The aim of this in vitro study was to assess the effects of pomegranate peel extract (PomeGr) on C. albicans growth and biofilm formation; in addition, the release of tyrosol and farnesol was investigated. The phenolic profile of PomeGr was assessed by high-performance liquid chromatography coupled to electrospray ionization mass spectrometry (HPLC-ESI-MS) analysis before and after exposure to C. albicans. Here, we showed that fungal growth, biofilm formation and AI release were altered by PomeGr treatment. Moreover, the phenolic content of PomeGr was substantially hampered upon exposure to fungal cells; particularly pedunculagin, punicalin, punicalagin, granatin, di-(HHDP-galloyl-hexoside)-pentoside and their isomers as well as ellagic acid-hexoside appeared highly consumed, suggesting their role as bioactive molecules against Candida. Overall, these new insights on the anti-Candida properties of PomeGr and its potential mechanisms of action may represent a relevant step in the design of novel therapeutic approaches against fungal infections.

Keywords: Candida albicans; anti-biofilm; in vitro; phenolic compounds; pomegranate; virulence.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antifungal Agents / pharmacology
  • Biofilms
  • Candida albicans
  • Farnesol* / pharmacology
  • Plant Extracts / pharmacology
  • Pomegranate*

Substances

  • Farnesol
  • 4-hydroxyphenylethanol
  • Antifungal Agents
  • Plant Extracts

Grants and funding

This research was partially supported by the POR FESR 2014-2020, POR FSE 2014-2020 (Accordi regionali di insediamento e sviluppo delle imprese: Bando 2019 in attuazione dell’art. 6 L.R. n.14/2014 e s.m.i.) within the “Progetto BOOM-2020: Micro-UNIMORE” of Incos-Cosmeceutica Industriale, Funo di Argelato, Bologna, Italy.